Citrus Red No. 2 is a synthetic dye that is used to color the skin of oranges and grapefruits. It is a mixture of two compounds: 1-(2,5-dimethylphenylazo)-2-naphthol (Sudan Red 7B) and 1-(4-diethylamino-2-methylphenylazo)-2-naphthol. The dye is applied to the fruit about 2-3 weeks before harvest. The dye is absorbed into the fruit and gives it a more uniform color. It is also believed to help prevent the fruit from becoming overripe. Citrus Red No. 2 has been studied extensively for its safety. The FDA has determined that it is safe for use on oranges and grapefruits at the recommended levels. However, some studies have shown that the dye may be carcinogenic in animals. More research is needed to determine if Citrus Red No. 2 is carcinogenic in humans. The dye is used because it helps to make the fruit more attractive to consumers and also helps to extend the shelf life of the fruit.'
ID Source | ID |
---|---|
PubMed CID | 22830 |
CHEMBL ID | 3560990 |
CHEBI ID | 82306 |
SCHEMBL ID | 9108481 |
SCHEMBL ID | 1486044 |
MeSH ID | M0050037 |
Synonym |
---|
ccris 1875 |
ci 12156 |
1-((2,5-dimethoxyphenyl)azo)-2-naphthol |
1-((2,5-dimethoxyphenyl)azo)-2-naphthalenol |
1-(1-(2,5-dimethoxyphenyl)azo)-2-naphthol |
brn 4510811 |
cerven rozpoustedlova 80 [czech] |
2-naphthol, 1-((2,5-dimethoxyphenyl)azo)- |
1-(2,5-dimethoxyphenylazo)-2-naphthol |
1-(2,5-dimethyloxyphenylazo)-2-naphthol |
hsdb 2948 |
2,5-dimethoxybenzeneazo-beta-naphthol |
solvent red 80 |
ci solvent red 80 |
einecs 228-778-9 |
2-naphthol, 1-(2,5-dimethoxyphenylazo)- |
citrus red |
2-naphthalenol, 1-((2,5-dimethoxyphenyl)azo)- |
2,5-dimethoxy-1-(phenylazo)-2-naphthol |
c.i. solvent red 80 |
citrus red no. 2 |
citrus red 2 |
2,5-dimethoxy-1-phenylazo-2-naphthol |
c.i. solvent red 80 (8ci) |
6358-53-8 |
1-[(e)-(2,5-dimethoxyphenyl)diazenyl]-2-naphthol |
c.i. 12156 |
SCHEMBL9108481 |
AKOS003581987 |
citrus red no.2 |
C19214 |
1-((2,5-dimethoxyphenyl)diazenyl)naphthalen-2-ol |
2qe5y68984 , |
2-naphthalenol, 1-(2-(2,5-dimethoxyphenyl)diazenyl)- |
unii-2qe5y68984 |
cerven rozpoustedlova 80 |
citrus red 2 [mi] |
citrus red 2 [mart.] |
citrus red 2 [hsdb] |
e-121 |
citrus red no. 2 [iarc] |
CHEBI:82306 |
SCHEMBL1486044 |
1-[(2,5-dimethoxyphenyl)diazenyl]-2-naphthol # |
GJUABKCEXOMRPQ-FMQUCBEESA-N |
2,5-dimethoxybenzeneazo-.beta.-naphthol |
2-naphthalenol, 1-[(2,5-dimethoxyphenyl)azo]- |
NCGC00357148-01 |
dtxsid6024838 , |
dtxcid10809925 |
tox21_303891 |
cas-6358-53-8 |
CHEMBL3560990 |
AKOS028109059 |
citrus red 2, analytical standard |
1-[(2,5-dimethoxyphenyl)azo]-2-naphthol |
1-(2-(2,5-dimethoxyphenyl)diazenyl)-2-naphthalenol |
1-[(2,5-dimethoxyphenyl)azo]-2-naphthalenol, 9ci |
1-[(2,5-dimethoxyphenyl)azo]-2-naphthalenol |
1-[(2,5-dimethoxyphenyl)diazenyl]naphthalen-2-ol |
1-(2,5-dimethoxy-phenylazo)-2-naphthol |
Q2653981 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 6.3261 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
acetylcholinesterase | Homo sapiens (human) | Potency | 35.5742 | 0.0025 | 41.7960 | 15,848.9004 | AID1347399 |
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 48.9662 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 1.4738 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
SMAD family member 2 | Homo sapiens (human) | Potency | 2.1872 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
SMAD family member 3 | Homo sapiens (human) | Potency | 2.1872 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 48.5577 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
AR protein | Homo sapiens (human) | Potency | 67.2985 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 6.4749 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 5.8574 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 4.6304 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 67.7288 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1259401 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 9.6885 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 8.6349 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 57.8067 | 0.0016 | 28.0151 | 77.1139 | AID1259385; AID1259395 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 20.6831 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 27.8401 | 0.0376 | 17.0823 | 61.1927 | AID1259364; AID1259388 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 8.6349 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 8.6349 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Glutamate receptor 2 | Rattus norvegicus (Norway rat) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (20.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (33.57) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |